Page 86 - Sohini Das

Bharat Biotech follows SII, reduces Covaxin price to Rs 400 for states

Earlier, the Bharat Biotech vaccine was priced at Rs 600 a dose

Serum cuts Covishield price by 25% for states, no change for pvt hospitals

Bharat Biotech is yet to announce any change in prices of Covaxin

Spiralling demand, leakages and a flourishing black market for remdesivir

Artificial shortages and brazen hawking of the drug on the streets at 15x the normal price rule the day as the official machinery tries desparately to stamp out the parallel market

Roche seeking fast approval of antibody cocktail in India to treat Covid

Co says demand for tocilizumab may exceed supplies it can provide

Return unused Covid-19 vaccine stock, govt tells private hospitals

Leading facilities in Mumbai, Delhi, Bengaluru have got communication in this regard

After states' objection, Centre asks vaccine manufacturers to lower prices

SII and Bharat Biotech had announced prices for state government procurement and for institutional sale to private hospitals

Centre clears the air on procurement of Covishield vaccine for states

Vaccination for those aged above 18 years could see a slow start in May

Bharat Biotech's Krishna Ella wants maximum price for its vaccine

Says the company would like to recover the costs incurred in clinical trials, and other things and reinvest the money into R&D to be ready for future pandemics

India could get its fourth vaccine by August, says NITI Aayog's V K Paul

Hyderabad-based Biological E's candidate has completed its phase one and two trials and is about to enter stage three

Serum prices Covishield at Rs 400 for Centre, Rs 600 for private hospitals

These are the prices for institutional sales, and not the maximum retail price, which will be announced later.

Cadila Healthcare testing two-shot regimen for ZyCoV-D, data likely by May

The company is conducting phase 3 efficacy trials on a three-dose regimen of its DNA plasmid technology-based Covid-19 vaccine, which is in its last leg

Covaxin neutralises the double-mutant coronavirus strain, says ICMR

The B.1.617 or 'double mutant' Indian variant carries two mutations, including the L452R and E484Q

Covaxin shows 100% efficacy against 'severe Covid-19', 78% overall

The Bharat Biotech candidate has also shown 70 per cent efficacy against asymptomatic infections, suggesting that it prevents transmission

Coronavirus vaccine shot may cost Rs 1,000 in private market: Sources

Could be priced at Rs 600-650/dose for institutional sales

Prioritise country first, PM Modi tells Covid-19 vaccine makers

"He has asked the industry to prioritise deliveries to meet the country's needs first and then focus on global supplies," said a person in the know, who did not wish to be named.

Manufacturers look to boost capacity as govt enhances vaccination scope

Firms work to secure raw material locally as imports remain a challenge

Serum, Bharat Biotech to get suppliers' credit for 300 mn Covid-19 doses

Govt okays Rs 4,500 cr upfront payment for 300 mn doses

Mankind Pharma eyes 50% revenue from chronic therapy drugs in 3 years

With the launch, the company has become the first Indian and second global firm to develop the drug, which is a generic version of Abbott's Duphaston

Covid-19: Remdesivir output to be doubled to 7.4 mn doses by April-end

18 new sites get DCGI consent to make antiviral used for treating Covid-19

From Sputnik V to Moderna, here's a snapshot of Covid-19 vaccines

Of this list, Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the aforementioned criteria